Retatrutide
Published date: 2026-05-22 10:27:51
|
Name | LY3437943 | CAS# | 2381089-83-2 |
|---|---|---|---|---|
| Price | $432.12/10mg $6847.04/1g | Purity | 98.77% | |
| Stocking Period |
3 Day | Stock | In Stock | |
| Product Webpage: | http://www.zhaokebio.com | |||
| Detail
Product Information
Retatrutide (development code LY3437943) is a first-in-class triple hormone receptor agonist peptide developed by Eli Lilly and Company, designed for the treatment of obesity and type 2 diabetes. It simultaneously activates three distinct metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG), delivering unprecedented synergistic effects on body weight reduction, glycemic control, and metabolic health. Retatrutide is a 39-amino-acid linear peptide engineered from the native oxyntomodulin sequence with strategic amino acid substitutions to optimize receptor binding profiles. The peptide is conjugated to a C20 fatty diacid moiety via a gamma-Glu-AEEA-Lys linker at Lys20, enabling strong albumin binding and an extended half-life of approximately 6 days, which supports once-weekly subcutaneous administration. Clinical trials have demonstrated record-breaking efficacy: Phase 2 trials showed up to 24.2% mean weight reduction at 48 weeks, while Phase 3 TRIUMPH-4 trial demonstrated 28.7% weight loss (71.2 lbs) at 68 weeks in participants with obesity and knee osteoarthritis. Shenzhen Zhaoke Biotechnology Co., Ltd. provides high-purity Retatrutide API (CAS No.: 2381089-83-2) with comprehensive analytical documentation for global pharmaceutical developers and research institutions. Key Selling Points: Triple Receptor Agonism-Simultaneously activates GIP, GLP-1, and glucagon receptors, delivering synergistic metabolic benefits that surpass single- or dual-agonist therapies. The unique triple mechanism enables superior weight loss and glycemic control. Breakthrough Weight Loss Efficacy-Phase 2: 24.2% weight loss at 48 weeks; Phase 3 TRIUMPH-4: 28.7% (71.2 lbs) at 68 weeks. Over 90% of participants achieved ≥10% weight loss at 12 mg dose. The weight loss curve had not plateaued at trial end. Osteoarthritis Pain Relief-Phase 3 TRIUMPH-4 demonstrated 75.8% reduction in WOMAC pain scores. Over 12% of treated participants became completely free of knee pain, significantly outperforming semaglutide (42% pain reduction). Once-Weekly Dosing-C20 fatty diacid conjugation enables albumin binding with a ~6-day half-life, supporting convenient once-weekly subcutaneous injection for improved patient adherence. Superior Metabolic Profile-Reduces A1C by up to 2.0%, lowers non-HDL cholesterol and triglycerides, and decreases systolic blood pressure. Total fat mass reduced by 26.1% with comparable lean mass preservation. Well-Tolerated Safety-Side effect profile consistent with GLP-1/GIP receptor agonists. Gastrointestinal events (nausea, diarrhea, vomiting) are the most common and typically transient. No new safety signals identified. |